Sign In
Buy CAH
$195.85
+0.97 (+0.498%)
At Close: Jun 03, 2026
Watch These 3 Stocks for Solid Earnings Acceleration
04:05pm, Wednesday, 26'th Feb 2025
Prairie Operating, Intuit and Cardinal Health are exhibiting strong earnings acceleration.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
10:45am, Friday, 21'st Feb 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
5 Broker-Loved Stocks to Keep an Eye on After Recent Analyst Upgrades
08:36am, Tuesday, 18'th Feb 2025
Investors should monitor stocks like Dana, Camping World, ABM, Cardinal Health and DXC for high returns.
Should Value Investors Buy Cardinal Health (CAH) Stock?
10:45am, Wednesday, 05'th Feb 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings
01:34pm, Tuesday, 04'th Feb 2025
Cardinal Health CAH reported better-than-expected second-quarter financial results on Thursday.
Cardinal Health Board of Directors Approves Quarterly Dividend
05:15pm, Monday, 03'rd Feb 2025
DUBLIN, Ohio , Feb. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital sur
Cardinal Health, Inc. (CAH) Q2 2025 Earnings Call Transcript
01:32pm, Thursday, 30'th Jan 2025
Cardinal Health, Inc. (NYSE:CAH ) Q2 2025 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Office
CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
12:11pm, Thursday, 30'th Jan 2025
Cardinal Health's second-quarter fiscal 2025 results benefit from solid Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Here's Why Cardinal Health (CAH) is a Strong Value Stock
10:46am, Thursday, 30'th Jan 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal (CAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 30'th Jan 2025
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stre
Wall Street Analysts Think Cardinal (CAH) Is a Good Investment: Is It?
10:31am, Thursday, 30'th Jan 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
Cardinal Health (CAH) Surpasses Q2 Earnings and Revenue Estimates
08:55am, Thursday, 30'th Jan 2025
Cardinal Health (CAH) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.82 per share a year ago.
Cardinal Health lifts 2025 profit forecast on specialty drugs demand
07:46am, Thursday, 30'th Jan 2025
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.
Cardinal Health Reports Second Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook
06:45am, Thursday, 30'th Jan 2025
Revenue decreased 4% to $55.3 billion; revenue increased 16% excluding the impact of the previously communicated large customer contract expiration GAAP 1 operating earnings were $549 million; GAAP di
Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term
10:55am, Wednesday, 29'th Jan 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
